Cognition in aging and neurodegenerative diseases reflects the net effect of multiple pathological, neuroplastic, and brain reserve processes. Penn's P30 Alzheimer's Disease Core Center (ADCC) is the foundation for many interactive clinical and basic research programs on AD and related disorders at Penn and beyond that investigate these processes. The Clinical Core's role is to support and promote this research to better characterize mechanisms of disease and resilience in patients and controls, to characterize the ways in which pathology clinically manifests in people over time, and to investigate ways to prevent or treat disease in order to maximize daily function and quality of life of older adults. The Clinical Core's base of operations is the Penn Memory Center (PMC), a multidepartmental clinical and clinical research outpatient center of the University of Pennsylvania Health System, where many of our research participants are recruited. We also have a longstanding research interest and commitment to an underserved Latino minority community through satellite recruitment in primary care practices in North Philadelphia and with the Education Core, we are expanding our outreach in the African American communities of West Philadelphia. The Clinical Core characterizes a longitudinal cohort of people with normal and abnormal brain aging who participate in our ADCC and its affiliated research programs by: a) applying standardized rating scales to measure past and current medical, cognitive, neurological, behavioral, and functional status, b) conducting and monitoring the clinical utility of neuroimaging studies and molecular-biochemical biomarkers for diagnosis, prognosis, and outcome c) establishing reliable and accurate consensus diagnosis, d) meticulously collecting and handling biospecimens, and e) recruiting and enrolling into affiliated research studies. The Clinical Core is the nexus for almost all of the clinical research conducted on AD and related disorders at Penn. It performs critical functions to support the mission of the Penn ADCC to increase the quality and quantity of AD-relevant research at Penn and beyond. Accordingly, it will continue to implement the following three aims:
Aim 1 : To identify, assess, and longitudinally evaluate patients from the earliest symptomatic stage of neurodegenerative dementia as well as individuals with normal cognition, gathering clinical data compliant with the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS), in addition to neuroimaging data, and biological material, including cerebrospinal fluid (CSF), blood, DNA and brain tissue.
Aim 2 : To facilitate the participation of individuals evaluated by the Clinical Core in collaborative research studies, including those of the Alzheimer's Disease Cooperative Study (ADCS) and the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Aim 3 : To integrate the collection and management of data and biological samples with the other cores in a manner that facilitates collaborative studies and sample sharing among the ADCs and other qualified investigators.

Public Health Relevance

AD and other related dementias are among the most common, feared, and costly conditions in later life. The Clinical Core of the Penn ADCC plays a central role in the assessment, diagnosis, research recruitment and longitudinal management of older adults with cognitive decline as well as their comparison to research participants with successful cognitive aging. Through a better understanding of healthy and diseased cognitive aging, we seek to improve the functioning and quality of life of older adults.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010124-23
Application #
8501183
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
23
Fiscal Year
2013
Total Cost
$682,074
Indirect Cost
$255,778
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Martini-Stoica, Heidi; Cole, Allysa L; Swartzlander, Daniel B et al. (2018) TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J Exp Med 215:2355-2377
He, Zhuohao; Guo, Jing L; McBride, Jennifer D et al. (2018) Amyloid-? plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29-38
Xie, Long; Das, Sandhitsu R; Wisse, Laura E M et al. (2018) Early Tau Burden Correlates with Higher Rate of Atrophy in Transentorhinal Cortex. J Alzheimers Dis 62:85-92
Gallagher, Michael D; Chen-Plotkin, Alice S (2018) The Post-GWAS Era: From Association to Function. Am J Hum Genet 102:717-730
Tropea, Thomas F; Xie, Sharon X; Rick, Jacqueline et al. (2018) APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. Mov Disord 33:289-297
Phillips, Jeffrey S; Das, Sandhitsu R; McMillan, Corey T et al. (2018) Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Hum Brain Mapp 39:691-708
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Gehrman, Philip; Gooneratne, Nalaka S; Brewster, Glenna S et al. (2018) Impact of Alzheimer disease patients' sleep disturbances on their caregivers. Geriatr Nurs 39:60-65
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Chen-Plotkin, Alice S (2018) Parkinson disease: Blood transcriptomics for Parkinson disease? Nat Rev Neurol 14:5-6

Showing the most recent 10 out of 720 publications